Stockscreener 앱 받기
2.07
6.76%
-0.15
시장 영업 전:
2.06
-0.010
-0.48%
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN
Needham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Thera rockets on early data for FT819 - The Pharma Letter
Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com
BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Fate Therapeutics Presents 6-Month Follow-up Data on First - GlobeNewswire
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance
Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges - TipRanks
Fate Therapeutics Unveils Q3 2024 Financial Highlights - TipRanks
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance
BMO cuts Fate Therapeutics stock target, keeps market rating on initial data - Investing.com UK
Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - MarketBeat
Fate Therapeutics: Q3 Earnings Snapshot - CT Insider
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - The Manila Times
Fate Therapeutics Highlights Cancer-selective, - GlobeNewswire
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewswire Inc.
Fate Therapeutics Presents Pan-tumor Targeting Preclinical - GlobeNewswire
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Inc (FATE) Worth Considering For The Next Few Weeks - Stocks Register
Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register
Global T-cell Therapy Market Trend [2024-2032] | Consumer Demographics - WICZ
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat
Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News
Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News
Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat
Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily
Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News
Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register
The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News
Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex
Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
0.93%
3.55%
자본화:
|
볼륨(24시간):